Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 9/20 | 0.57 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611519 | 0.85 | NTSR1 (0.51) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL29677036 | 0.84 | OPRM1 (0.48) | NTSR1NTSR2OPRD1OPRM1SORT1 | |
| SCHEMBL8936991 | 0.84 | XIAP (0.51) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL8936997 | 0.84 | XIAP (0.51) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL29612056 | 0.83 | NTSR1 (0.48) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL29611888 | 0.81 | NTSR2 (0.47) | NTSR1NTSR2OPRM1OPRK1SORT1 | |
| SCHEMBL29611889 | 0.81 | CAPN1 (0.48) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL29802105 | 0.81 | ACE (0.48) | NTSR1NTSR2OPRM1OPRK1 | |
| SCHEMBL29612048 | 0.80 | NTSR1 (0.49) | NTSR1NTSR2OPRD1OPRM1OPRK1 | |
| SCHEMBL13697491 | 0.80 | NPY2R (0.46) | NTSR1NTSR2SORT1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308716-B1 | HYBRID MOLECULE COMPRISING A FIBRIN-DERIVED CITRULLINATED PEPTIDE AND AN ANTIBODY OR ANTIBODY FRAGMENT WHICH BINDS TO CD38 AND/OR CD138, AND USES THEREOF | UNIV TOULOUSE 3 PAUL SABATIER (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4308715-B1 | HYBRID MOLECULE COMPRISING AN ANTIBODY FC FRAGMENT AND AT LEAST ONE FIBRIN-DERIVED CITRULLINATED PEPTIDE, AND USES THEREOF | UNIV TOULOUSE 3 PAUL SABATIER (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20260091122-A1 | Hybrid Molecule Comprising an Antibody FC Portion and at Least One Peptide Binding to a Self-Reactive Lymphocyte Involved in Autoimmune Dermatitis, and Uses Thereof | Universite Toulouse III – Paul Sabatier (FR) | 2026-04-02 | — | — | US | disclosed |
| EP-4593865-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NFL-TBS40-63PEPTIDE, VARIANTS OR SALTS THEREOF AND ALANINE | Gliocure (FR) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025147760-A1 | PEPTIDES, HYDROGELS, PHOTOACTIVATABLE HYDROGEL PRECURSORS, METHODS OF PREPARATION AND DEVICES FOR DELIVERY THEREOF, AND METHODS OF TREATMENT THEREWITH | OTTAWA HEART INSTITUTE RESEARCH CORPORATION (CA) | 2025-07-17 | — | — | WO | disclosed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025106566-A2 | FLUOROGENIC BIFUNCTIONAL PROBE OF PROTEASE ACTIVITY | Life Technologies Corporation (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025059553-A1 | CHIMERIC MOLECULES FOR COMPLEMENT IMMUNE RECRUITMENT | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119534852-A | Quantitative detection method for low-abundance host cell residual protein of monoclonal antibody drug | 湖州申科生物技术股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025030099-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| CN-114746451-A | TGF-beta/PD-L1 bispecific binding proteins | 上海岸迈生物科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114728073-A | Selective release of drug from internalized conjugates of biologically active compounds | 思进股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114656573-A | Deimmunized shiga toxin a subunit scaffolds and cell targeting molecules comprising them | 分子模板公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3157544-B1 | USE OF A NEUROFILAMENT PEPTIDE FOR TARGETING NEURAL STEM CELLS | UNIV ANGERS (FR) | 2022-06-01 | — | — | EP | disclosed |
| CN-107849096-B | Deimmunized shiga toxin a subunit scaffolds and cell targeting molecules comprising them | 分子模板公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20220133847-A1 | COMPOSITIONS AND METHODS FOR ALLEVIATING PAIN | UNITED STATES DEPARTMENT OF VETERANS AFFAIRS | 2022-05-05 | — | — | US | disclosed |
| CN-114395051-A | Ligase fusion protein and application thereof | 启德医药科技（苏州）有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-109627290-B | Alpha spiral self-assembly short peptide and application thereof in protein purification | 华南理工大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-114207137-A | Controlled transgene expression in regulatory T cells | 桑格摩生物治疗股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114106091-A | Protein analogs and conjugates thereof | 正大天晴药业集团股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091122-A1 | Hybrid Molecule Comprising an Antibody FC Portion and at Least One Peptide Binding to a Self-Reactive Lymphocyte Involved in Autoimmune Dermatitis, and Uses Thereof | DSG1, CD74, FCGR3B | NTSR1 995/4885NTSR2 2096/4885OPRD1 2597/4885 |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | NTSR1 486/4885NTSR2 794/4885OPRD1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.